Can small animal imaging accelerate drug development?
暂无分享,去创建一个
[1] Gerhard Gründer,et al. Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography , 1997, Neuropsychopharmacology.
[2] N. Volkow,et al. PET and drug research and development. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] S. Larson,et al. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: A method to modulate gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] R. Weissleder,et al. Human transferrin receptor gene as a marker gene for MR imaging. , 2001, Radiology.
[5] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[6] Gaetano T. Montelione,et al. Structural genomics: An approach to the protein folding problem , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] T. Jones,et al. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. , 2001, Drug discovery today.
[8] Arion F. Chatziioannou,et al. Molecular imaging of small animals with dedicated PET tomographs , 2001, European Journal of Nuclear Medicine and Molecular Imaging.
[9] P. Price,et al. PET for in vivo pharmacokinetic and pharmacodynamic measurements. , 2002, European journal of cancer.
[10] The Potential Uses of Radiopharmaceuticals in the Pharmaceutical Industry , 1993 .
[11] S. Schreiber,et al. Printing proteins as microarrays for high-throughput function determination. , 2000, Science.
[12] R. Buckley. Gene therapy for SCID—a complication after remarkable progress , 2002, The Lancet.
[13] W Vaalburg,et al. Drug development, radiolabelled drugs and PET. , 1999, Annals of medicine.
[14] Johan Nuyts,et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] A. Padhani,et al. The RECIST criteria: implications for diagnostic radiologists , 2001 .
[16] M. Pomper,et al. Radiolabeled neuronal nitric oxide synthase inhibitors: synthesis, in vivo evaluation, and primate PET studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] T. Grist,et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. , 2001, Radiology.
[18] B. Kreider. Chapter 22. Proteomics: defining protein function in the post genomics era , 2001 .
[19] Gregory S Karczmar,et al. MRI of the tumor microenvironment , 2002, Journal of magnetic resonance imaging : JMRI.
[20] Parvaneh Saeedi,et al. A physical map of the mouse genome , 2002, Nature.
[21] A R Padhani,et al. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. , 2001, The British journal of radiology.
[22] C. Contag,et al. It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology , 2002, Journal of magnetic resonance imaging : JMRI.
[23] Jeff W M Bulte,et al. In Vivo Magnetic Resonance Tracking of Magnetically Labeled Cells after Transplantation , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[24] R Weissleder,et al. Improvement of MRI probes to allow efficient detection of gene expression. , 2000, Bioconjugate chemistry.
[25] R Myers,et al. Dedicated small animal scanners: a new tool for drug development? , 2002, Current pharmaceutical design.
[26] S. Osman,et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. , 2001, Current pharmaceutical design.
[27] H. Dittmann,et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[28] D Artemov,et al. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. , 2001, Neoplasia.
[29] J. Hietala. Ligand-receptor interactions as studied by PET: implications for drug development. , 1999, Annals of medicine.
[30] W Vaalburg,et al. Positron emission tomography in drug development and drug evaluation. , 2000, Current pharmaceutical design.
[31] Wei Li,et al. Noninvasive imaging of protein–protein interactions in living animals , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Weissleder. Scaling down imaging: molecular mapping of cancer in mice , 2002, Nature Reviews Cancer.